The majority of Bavarian Nordic's research programmes are based
on the company's patented technology; MVA-BN®.
MVA-BN® is the active ingredient in IMVAMUNE® - the company's
third-generation smallpox vaccine.
MVA-BN® in its recombinant form is Bavarian Nordic's viral
vector and is used in most of the group's development programmes
against smallpox, cancer and infectious diseases.
